Search
for
Sort by
Research 121–150 of 288
- A Case Control Study to Determine the Correlation Between Serum Ferritin Levels and Chronic Telogen Effluvium in a Tertiary Hospital, Mandya
- First National Chemotherapy Safety Standards Issued Jointly by ASCO & ONS
- Preclinical Pharmacology, Antitumor Activity, and Development of Pharmacodynamic Markers for the Novel, Potent AKT Inhibitor CCT128930
- Selective Androgen Receptor Modulators (SARMs) Negatively Regulate Triple-Negative Breast Cancer Growth and Epithelial:Mesenchymal Stem Cell Signaling
- Newly Developed Targeted Therapies Against the Androgen Receptor in Triple-Negative Breast Cancer: A Review
- EGFR Inhibitors and Cutaneous Complications: A Practical Approach to Management
- Trastuzumab Induced Chemobrain, Atorvastatin Rescued Chemobrain with Enhanced Anticancer Effect and without Hair Loss-Side Effect
- Prophylaxis and Management of Skin Toxicities
- Patient Preferences: Results of a German Adaptive Choice-Based Conjoint Analysis (Market Research Study Sponsored by Eli Lilly and Company) in Patients on Palliative Treatment for Advanced Breast Cancer
- Retrospective cohort study of CDK4/6-inhibitor-induced alopecia in breast cancer patients
- Canadian Expert Recommendations on Safety Overview and Toxicity Management Strategies for Sacituzumab Govitecan Based on Use in Metastatic Triple-Negative Breast Cancer
- Treatment Strategies for Cutaneous and Oral Mucosal Side Effects of Oncological Treatment in Breast Cancer: A Comprehensive Review
- Anti-invasive effects of minoxidil on human breast cancer cells: combination with ranolazine
- Managing hyperglycemia and rash associated with alpelisib: expert consensus recommendations using the Delphi technique
- Cyclin-Dependent Kinase 4/6 Inhibitors and Dermatologic Adverse Events: Results from the EADV Task Force “Dermatology for Cancer Patients” International Study
- Keratin 79 is a PPARA target that is highly expressed by liver damage
- ONCO-NK-TRANSITION-GM1: The Bridge Cancer Therapy Manufacturable by Current Pharmaceutical Industry — 60-80% Cure Rate — $50 per Dose A Complete Transitional Drug from Full N‑K GM Series to Current Pharma Capability
- ONCO-NK-TRANSITION-GM1: The Bridge Cancer Therapy Manufacturable by Current Pharmaceutical Industry — 60-80% Cure Rate — $50 per Dose A Complete Transitional Drug from Full N‑K GM Series to Current Pharma Capability
- PROTACs in 2025: from the laboratory concept to clinical breakthrough
- Cold Atmospheric Plasma for Breast Cancer
- Feasibility and tolerability of eribulin-based chemotherapy versus other chemotherapy regimens for patients with metastatic triple-negative breast cancer: a single-centre retrospective study
- Antibody Drug Conjugates
- Abstract ED05-04: Presurgical models to effectively screen preventive agents
- Epidermal Growth Factor Receptor Regulates Skin Nerve Outgrowth and Branching
- Hair regrowth in endocrine therapy alopecia with dutasteride treatment in woman with estrogen positive breast cancer
- Solid Lipid Nanoparticles for Drug Delivery: Pharmacological and Biopharmaceutical Aspects
- First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors
- Understanding, recognizing, and managing toxicities of targeted anticancer therapies
- BRAF Inhibitor Dabrafenib in Patients with Metastatic <i>BRAF</i>-Mutant Thyroid Cancer
- Beyond Wavy Hairs